California, US-based biotech True North Therapeutics has appointed Jeff Ajer to its board of directors as an independent director.
Ajer currently serves as executive vice president and chief commercial officer of BioMarin, and was previously the firm’s vice president of commercial operations for the Americas.
He first joined BioMarin in 2005 from Genzyme, where he was vice president of global transplant operations, and prior to this held a series of sales, marketing and operations positions at SangStat Medical Corporation and ICN Pharmaceuticals.
Nancy Stagliano, chief executive officer of True North Therapeutics, said: “We are delighted that Jeff has joined our board.
“We believe his extensive commercial experience with products for rare diseases, which includes over 11 years at BioMarin where he built the company’s commercial infrastructure and led successful drug launches, will be invaluable as we continue to build a pipeline of innovative medicines designed to treat Complement-mediated rare diseases.”